Champion Sébastien, Zieger Laëtitia, Hemery Caroline
Intensive Care Unit, Parly 2 Clinic, Ramsay Générale de Santé, 78150 Le Chesnay, France.
Ann Card Anaesth. 2018 Jan-Mar;21(1):8-14. doi: 10.4103/aca.ACA_122_17.
The role of prophylaxis for postoperative nausea and vomiting (PONV) in cardiac surgery is under debate.
To study the risk factors for PONV after cardiac surgery and the role of betamethasone with or without droperidol for its prevention.
Randomized open-label controlled study comparing standard care with PONV prophylaxis from February to November 2016.
Five hundred and two patients with planned nonemergent cardiac surgery were included.
In the intervention arm, PONV prophylaxis (4 mg betamethasone with/without 0.625 mg droperidol) was administered in high-risk patients (two or more risk factors). Patients in the control arm were treated as per routine hospital practices.
Female sex, past history of PONV, and migraines were associated with a significantly increased risk of PONV, while motion sickness, smoking status, and volatile anesthetics were not. Pain and treatment with nefopam or ketoprofen were associated with an increased risk of PONV. PONV was less frequent in the active arm compared to controls (45.5% vs. 54.0%, P = 0.063; visual analogic scale 10.9 vs. 15.3 mm, P = 0.043). Among the 180 patients (35.6%) with ≥2 risk factors, prophylaxis was associated with reduced PONV (intention-to-treat: 46.8% vs. 67.8%, P = 0.0061; per-protocol: 39.2% vs. 69%, P = 0.0002). In multivariate analysis, prophylaxis was independently associated with PONV (odds ratio [OR]: 0.324, 95% confidence interval: 0.167-0.629, P = 0.0009), as were female sex, past history of PONV, and migraines (OR: 3.027, 3.031, and 2.160 respectively). No drug-related side effects were reported.
Betamethasone with/without droperidol was effective in decreasing PONV in high risk cardiac surgical patients without any side effect.
心脏手术中术后恶心呕吐(PONV)预防措施的作用存在争议。
研究心脏手术后PONV的危险因素以及倍他米松联合或不联合氟哌利多预防PONV的作用。
2016年2月至11月进行的一项随机开放标签对照研究,比较标准护理与PONV预防措施。
纳入502例计划进行非急诊心脏手术的患者。
在干预组中,对高危患者(两个或更多危险因素)给予PONV预防措施(4mg倍他米松联合/不联合0.625mg氟哌利多)。对照组患者按照医院常规做法进行治疗。
女性、PONV既往史和偏头痛与PONV风险显著增加相关,而晕动病、吸烟状况和挥发性麻醉剂则无此关联。疼痛以及使用奈福泮或酮洛芬治疗与PONV风险增加相关。与对照组相比,干预组PONV发生率较低(45.5%对54.0%,P = 0.063;视觉模拟评分10.9对15.3mm,P = 0.043)。在180例(35.6%)有≥2个危险因素的患者中,预防措施与PONV减少相关(意向性分析:46.8%对67.8%,P = 0.0061;符合方案分析:39.2%对69%,P = 0.0002)。在多变量分析中,预防措施与PONV独立相关(比值比[OR]:0.324,95%置信区间:0.167 - 0.629,P = 0.0009),女性、PONV既往史和偏头痛也与之相关(分别为OR:3.027、3.031和2.160)。未报告与药物相关的副作用。
倍他米松联合/不联合氟哌利多能有效降低高危心脏手术患者的PONV发生率,且无任何副作用。